EurekAlert! -
9 May 2016 06:00
(University of Southern California) The latest drugs that treat the blood-borne illness hepatitis C can cure it, but their price tag remains a point of contention for insurers and government health care officials. A series of studies in this month's special hepatitis C edition of the American Journal of Managed Care show multiple long-term benefits of financing the cure for patients and early screening.
Share this Article